On April 17, 2026 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, reported that two poster presentations highlighting its ADC pipeline will be delivered at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) 2026 presentations will showcase NEOK’s emerging pipeline of next-generation ADCs engineered to target proteins broadly expressed across tumor types with high unmet need. The company will present new findings for its two lead bispecific candidates: NEOK001, a first-in-class "2+2" bispecific ADC designed to target B7-H3 and ROR1-expressing tumors, and NEOK002, a "1+1" bispecific ADC targeting EGFR (epidermal growth factor receptor) and MUC1 (Mucin 1)-expressing solid tumors. Both therapies utilize Synaffix’s proprietary, validated linker-payload technology with a DAR 4 Topoisomerase-1 (Topo-1) inhibitor, exatecan (SYNtecan E ).
Both programs have received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and NEOK plans to initiate Phase 1 clinical trials in 2Q 2026, with initial clinical data readouts anticipated in 2027. Both of NEOK’s bispecific ADC candidates will enter the clinic on a foundation of promising preclinical studies, where they have demonstrated superior in vivo efficacy in solid tumors compared to traditional monovalent ADCs.
Preclinical data will be shared in two separate poster presentations on April 20 during the session titled "Antibody Drug Conjugates and Linker Engineering 2" at AACR (Free AACR Whitepaper) 2026. Highlights of the presentations include:
Poster 1724: NEOK001: A first-in-class B7-H3xROR1 bispecific ADC demonstrated enhanced efficacy and promising tolerability
Potent dual‑target cytotoxicity and strong bystander killing, supporting activity in heterogeneous solid tumors
Broad efficacy across 38 PDX models, achieving 84% tumor growth inhibition and 53% deep tumor regression across nine major cancer types
Outperformed clinical benchmark ADCs, including I‑Dxd and zilovertamab vedotin, and successfully regressed I‑Dxd-treated regrowing tumors
Observed favorable safety profile in GLP toxicology studies (HNSTD: 60 mg/kg) with stable DAR and predictable pharmacokinetics
Poster 1726: NEOK002: Designing an EGFRxMUC1 Bispecific TOP1i ADC with Promising Anti-Tumor Activity and Enhanced Therapeutic Window
Dual-targeting design enhances binding and internalization in dual-positive tumor cells while reducing off‑tumor EGFR engagement
Robust antitumor activity across 36 PDX models, achieving tumor regressions in 78%, including KRAS‑mutant and heavily pretreated tumors
Favorable safety profile with minimal impact on keratinocyte proliferation and reduced inhibition of EGFR signaling versus cetuximab-based ADCs
Strong combination potential sotorasib, enabling extended tumor regression for 58 days in KRAS G12C-mutant models
"These preclinical findings underscore the potential of our next-generation ADC pipeline to overcome the limitations of conventional monovalent designs," said Mayank Gandhi, MD, CEO of NEOK Bio. "As we prepare to accelerate both candidates into clinical development, we look forward to sharing their differentiated mechanisms and compelling pre-clinical activity at ACCR 2026."
(Press release, Neok Bio, APR 17, 2026, View Source [SID1234664498])